Skip to Main Content

Paper Details

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Proc Natl Acad Sci U S A
102
2017
Author NameAffiliation
Udupi A RamagopalAlbert Einstein College of Medicine
Jeffrey B BonannoAlbert Einstein College of Medicine
Steven C AlmoAlbert Einstein College of Medicine
  • 1 - 3

Datasets

Release 1.2